ImmunoQure AG – rare natural antibodies derived from patients for patients.

ImmunoQure AG is a young biotech company spearheading the research and development of human-derived antibodies (HD-MABs) for the treatment of human diseases. Through our unique access to rare patient populations, we are able to identify patients harboring naturally optimized antibodies against key drug targets that are involved in preventing a number of human diseases.

NEWS: ImmunoQure AG announces publication in Cell of naturally occurring patient-derived autoantibodies that limit human diseases

Jump to the News

SCIENCE

ImmunoQure is focusing on the discovery of patient-selected antibodies for the treatment of inflammatory and autoimmune diseases.
READ MORE

PARTNERS

ImmunoQure is collaborating with leading academic centers in Europe. The company is supported by HS LifeSciences, an experienced investor in the field of biotechnology.
READ MORE

PEOPLE

Meet our people, an international group of exceptional individuals with outstanding scientific and business backgrounds who bring a remarkable pool of experience to ImmunoQure.
READ MORE

JOIN US

To drive the development of our projects and the innovative aspects of our technology, we are looking for exceptional people with the best expertise to join our team.
READ MORE